| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4818 | Sniper(brd4)-1 | Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Eraser (SNIPER), acting as a a protein degradation inducer of bromodomain-containing protein 4 (BRD4) |
|
| DCC4819 | Sniper(ch6) | Novel fused proteins degrader of the His-tagged CRABP-II and Smad2 in cells |
|
| DCC4820 | Sniper(crabp)-11 | Novel potent degrader of the mitochondrial CRABP-II protein |
|
| DCC4821 | Sniper(er)-87 | Novel potent and selective degrader of the ERα protein |
|
| DCC4822 | Sniper(pde4)-9 | Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Eraser (SNIPER), acting as a a protein degradation inducer of phosphodiesterase-4 (PDE4) |
|
| DCC4823 | Snri-h05 | Novel potent serotonin and noradrenaline reuptake inhibitor (SNRI) with moderate 5-HT2A antagonist activity for anti-depression |
|
| DCC4824 | sns-oh | Inducer of apoptosis in neuroblastoma cells through inhibition of AKT signaling pathway |
|
| DCC4825 | Snu-bp | Novel agonist of PPAR-gamma, inhibiting lipopolysaccharide (LPS)-induced NO production and pro-inflammatory cytokines, potentiating interleukin-4-induced arginase-1 expression, promoting microglial polarization toward to an M2 anti-inflammatory phenotype |
|
| DCC4826 | Snx2-1-108 | Highly selective inhibitor of CDK8 and its isoform CDK19 |
|
| DCC4827 | So1989 | Novel macrophage modulator, inhibiting inflammation and M1 polarization of macrophages, restoring the balance between M1-polarized and M2-polarized macrophages in high fat diets (HFD)-induced obese mice resulting in the improvement of adipose inflammation |
|
| DCC4828 | soblidotin | Inhibitor of tubulin polymerization, resulting in cell cycle arrest and induction of apoptosis |
|
| DCC4829 | Sobuzoxane | Orally available active prodrug of ICRF-154, interferring with topoisomerase II activity prior to the formation of intermediate cleavable DNA-enzyme complexes during the catalytic cycle resulting in tumor cell growth inhibition |
|
| DCC4830 | Sod1-derlin-1 Inhibitor 56-20 | Novel potent inhibitor of SOD1-Derlin-1 interaction |
|
| DCC4831 | Sod1-derlin-1 Inhibitor 56-26 | Novel potent inhibitor of SOD1-Derlin-1 interaction |
|
| DCC4832 | Sodelglitazar | PPARdelta receptor agonist |
|
| DCC4833 | Sodium Dehydrocholate | Hepatoprotective and choleretic agent |
|
| DCC4834 | Sodium Oxybate | Narcolepsy agent, being used to treat catalepse and daytime sleepiness in patients with narcolepsy |
|
| DCC4835 | Solanidine | Natural tumor antagonistic steroidal alkaloid, inducing typical cellular apoptotic hallmarks and cell cycle blockage at S-G2/M phase, activating nuclear import of DFF-40 mediated nucleosomal disruption and cell demise |
|
| DCC4836 | Solimastat | Novel oral, broad-spectrum matrix metalloproteinase inhibitor (MMPI), being >10-fold more active than marimastat in inhibiting the processing of cell-bound TNF-alpha |
|
| DCC4837 | Somapacitan | Novel long-acting, reversible albumin-binding growth hormone (GH) derivative for treatment of growth hormone dificiency |
|
| DCC4838 | Somatoprim | Unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reducing GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. |
|
| DCC4839 | Somcl-668 | Novel potent and selective allosteric modulator of sigma-1 receptor |
|
| DCC4840 | Somcl-863 | Novel, selective and orally bioavailable c-Met inhibitor, exhibiting antitumor activity both in vitro and in vivo |
|
| DCC4841 | Sonedenoson | A2A adenosine receptor agonist |
|
| DCC4842 | Sophoradin | Natural analgesic, antipyretic, anti-inflammatory, and anti-tumor agent |
|
| DCC4843 | Sophorafavanone A | Inhibitor of constitutive and inducible STAT3 activation through the activation of SHP-2 tyrosine phosphatase |
|
| DCC4844 | Sophoraflavanone B | Natural inhibitor of the Kv1.3 channels in a concentration-dependent manner |
|
| DCC4845 | soraphinol A | Human norepinephrine transporter blocker |
|
| DCC4846 | sori-20041 | DAT modulator, being unique in affecting substrate uptake without impacting efflux |
|
| DCC4847 | sori-9804 | Novel partial inhibitor of amphetamine-induced dopamine release |
|
